SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
机构：[1]Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China[2]Thoracic MedicineDepartment I, Henan Cancer Hospital, Changsha, China河南省肿瘤医院[3]GCP Center, HenanCancer Hospital, Changsha, China[4]Second Ward of Oncology, The First AffiliatedHospital of Zhengzhou University, Zhengzhou, China[5]Department of Tumor Radiotherapy,Anhui Chest Hospital, Hefei, China[6]General Department, Beijing ChestHospital, Capital Medical University, Beijing, China[7]Integrative Cancer Centre,Guangzhou University of Chinese Medicine First Affiliated Hospital, Guangzhou, China[8]Internal Medicine-Oncology, Sir Run Run Shaw Hospital Zhejiang University School ofMedicine, Hangzhou, China[9]Medical Oncology, Jinan Central Hospital, Jinan, China[10]Department of Oncology, The Second Affiliated Hospital of Army Military MedicalUniversity, Chongqing, China[11]The Third Ward of Respiratory Medicine, HenanCancer Hospital, Zhengzhou, China[12]Clinical Research and Development, JiangsuHengrui Medicine Co., Ltd., Shanghai, China
第一作者机构：[1]Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China
推荐引用方式(GB/T 7714)：
J. Feng,J. Chen,K. Li,et al.SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study[J].ANNALS OF ONCOLOGY.2021,32:S995-S995.doi:10.1016/j.annonc.2021.08.1880.
APA：
J. Feng,J. Chen,K. Li,X. Li,X. Min...&P. Liu.(2021).SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study.ANNALS OF ONCOLOGY,32,
MLA：
J. Feng,et al."SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study".ANNALS OF ONCOLOGY 32.(2021):S995-S995
医学